Typically measured during first-trimester assessments at 11‒13 weeks, lower levels of PAPP-A have been linked with a high risk of adverse fetal complications, especially preterm birth, as well as increased incidence of maternal hypertensive disorders such as preeclampsia during pregnancy.61 This evidence concerns the gene PAPPA and preeclampsia.